Dosing Recommendations for Norvir (Ritonavir) in Pediatric Patients One Month to Two Years of Age
On October 6, 2005, the Food and Drug Administration approved dosing recommendations for Norvir (ritonavir) in pediatric patients one month to two years of age. The major revisions to the package insert include the following:
This section was modified to include pharmacokinetic data in children 1 month to 2 years of age. The new Clinical Pharmacology section for Pediatric Patients reads as follows:
Steady-state pharmacokinetics were evaluated in 37 HIV infected patients ages 2 to 14 years receiving doses ranging from 250 mg/m2 twice-daily to 400 mg/m2 twice daily in PACTG Study 310, and in 41 HIV-infected patients ages 1 month to 2 years at doses 350 and 450 mg/m2 twice daily in PACTG Study 345. Across dose groups, ritonavir steady-state oral clearance (CL/F/m2) was approximately 1.5 to 1.7 times faster in pediatric patients than in adult subjects. Ritonavir concentrations obtained after 350 to 400 mg/m2 twice daily in pediatric patients > 2 years were comparable to those obtained in adults receiving 600 mg (approximately 330 mg/m2) twice daily. The following observations were seen regarding ritonavir concentrations after administration with 350 or 450 mg/m2 twice daily in children < 2 years of age. Higher ritonavir exposures were not evident with 450 mg/m2 twice daily compared to the 350 mg/m2 twice daily. Ritonavir trough concentrations were somewhat lower than those obtained in adults receiving 600 mg twice daily. The area under the ritonavir plasma concentration-time curve and trough concentrations obtained after administration with 350 or 450 mg/m2 twice daily were approximately 16% and 60% lower, respectively, than that obtained in adults receiving 600 mg twice daily.
The following information was added under the section of Pediatric Use subsection:
In HIV-infected patients age > 1 month to 21 years, the antiviral activity and adverse event profile seen during clinical trials and through postmarketing experience were similar to that for adult patients.
The following information was added under the section of Pediatric Use subsection. Of note, the treatment-emergent adverse events and laboratory abnormalities shown in the label reflect the summary of the adverse events and laboratory abnormalities observed in pediatric studies M95-310, PACTG 366, and PACTG 345.
Treatment-Emergent Adverse Events
Norvir has been studied in 265 pediatric patients > 1 month to 21 years of age. The adverse event profile observed during pediatric clinical trials was similar to that for adult patients.
Vomiting, diarrhea, and skin rash/allergy were the only drug-related clinical adverse events of moderate to severe intensity observed in > 2% of pediatric patients enrolled in Norvir clinical trials.
The following Grade 3-4 laboratory abnormalities occurred in > 3% of pediatric patients who received treatment with Norvir either alone or in combination with reverse transcriptase inhibitors: neutropenia (9%), hyperamylasemia (7%), thrombocytopenia (5%), anemia (4%), and elevated AST (3%).
Dosage and Administration
The section of Pediatric Patients has been modified to include dosing recommendations for children > 1 month to 2 years of age. The new Dosage and Administration section for Pediatric Patients is:
Ritonavir should be used in combination with other antiretroviral agents (see General Dosing Guidelines). The recommended dosage of ritonavir in children > 1 month is 350 to 400 mg/m2 twice daily by mouth and should not exceed 600 mg twice daily. Ritonavir should be started at 250 mg/m2 and increased at 2 to 3 day intervals by 50 mg/m2 twice daily. If patients do not tolerate 400 mg/m2 twice daily due to adverse events, the highest tolerated dose may be used for maintenance therapy in combination with other antiretroviral agents, however, alternative therapy should be considered. When possible, dose should be administered using a calibrated dosing syringe.